Aleta Biotherapeutics

Aleta Biotherapeutics is pioneering a novel approach to overcome limitations of CAR T-cell therapies, particularly antigen escape and relapse. Its proprietary CAR T Engager (CTE) proteins are off-the-shelf biologics that bind to cancer cells and 're-target' them for destruction by a patient's existing CAR T cells, effectively boosting antigen density and preventing resistance. With its lead asset, ALETA-001, in a Phase I/II trial supported by Cancer Research UK and holding key regulatory designations, the company is initially targeting the significant unmet need in lymphoma and myeloma, with a preclinical pipeline extending into AML and solid tumors. Aleta is a private company leveraging a capital-efficient, asset-centric model to advance its platform.

CAR T Engager (CTE) platform: Off-the-shelf, bispecific/multispecific biologic proteins that bind to cancer cells via a tumor antigen and simultaneously present the target antigen (e.g., CD19) for a patient's existing CAR T cells, enhancing antigen density and killing efficacy.

Aleta competes in the post-CAR-T relapse space with companies developing bispecific antibodies (e.g., Blincyto for ALL, others in development), new CAR-T constructs targeting alternative antigens, and other T-cell engager platforms. Its differentiation lies in its specific design to work in tandem with an already-infused CAR-T product, offering a potentially simpler, off-the-shelf booster therapy.